Navigation Links
Genetic septet in control of blood platelet clotting
Date:6/22/2010

In what is believed to be the largest review of the human genetic code to determine why some people's blood platelets are more likely to clump faster than others, scientists at Johns Hopkins and in Boston have found a septet of overactive genes, which they say likely control that bodily function.

"Our results give us a clear set of new molecular targets, the proteins produced from these genes, to develop tests that could help us identify people more at risk for blood clots and for whom certain blood-thinning drugs may work best or not," says co-senior study investigator and cardiologist Lewis Becker, M.D.

"We can even look toward testing new treatments that may speed up how the body fights infection or recovers from wounds," says Becker, a professor at the Johns Hopkins University School of Medicine.

Platelets are key to fighting infection and sealing wounds and, adversely, can speed up cardiovascular diseases that can lead to potentially fatal heart attacks or strokes.

Reporting in the issue of Nature Genetics online June 7, researchers tested the platelet "stickiness" in blood samples from some 5,000 American men and women and compared the results to some 2.5 million single possible changes in the human genetic code to see which genes stood out across the entire group as speeding up or slowing down platelet clumping. Study participants included both whites and blacks with no previously known chronic health problems, representing what researchers say is "a solid cross-section of American society."

Seven genes were found on their own to be hugely significant in affecting how fast or how long it took for platelets to stick together or how many platelets would clump. (The seven were more than 500 million times more likely than other genes to impact clumping, whereas the next most influential genes, a set of 15, were found to be 10,000 times more likely to affect clumping function.)

According to Becker, three of the seven genes had been previously reported as having some role in platelet aggregation, but "it was not until now that we put together all the major pieces of the genetic puzzle that will help us understand why some people's blood is more or less prone to clot than others and how this translates into promoting healing and stalling disease progression."

He points out that the latest study was made possible by combining data from two longstanding studies of why seemingly healthy people get heart disease. Results came from some 2,800 white men and women participating in the Massachusetts-based Framingham Heart Study, all since 2003, when researchers in the decades-long study began collecting platelet samples. Platelet samples came from another 2,000 similar participants, including 800 blacks, enrolled in the Genetic Study of Aspirin Responsiveness (GeneSTAR) under way at Johns Hopkins since 2002 and led by Becker's wife and study co-investigator Diane Becker, M.P.H., Sc.D., a professor at the both Hopkins' School of Medicine and the University's Bloomberg School of Public Health.

According to Diane Becker, a health epidemiologist, generalizing the data to the broader American population was only made possible by combining these large study populations, as neither on their own was sufficient for such a genome-wide scan.

In the study, platelet samples were tested for their "stickiness" in response to adding various concentrations of three chemicals commonly found in the blood, including adenosine diphosphate, or ADP, which is an energy molecule released by platelets into the blood to attract and clump with other platelets; epinephrine, a stress hormone tied to inflammation and vascular disease; and collagen, the most common protein in the human body.

Clumping results were then cross-matched with results from gene chip surveys of the human genome, which allow researchers to sort through millions of different genetic modifications to see which specific genes are more active than others. Diane Becker says the genetic analysis alone was a massive undertaking and took some two years to complete.

Lewis Becker says the teams' next steps are to test various platelet antagonists, or blood-thinning agents, like aspirin, the most common drug treatment in heart and vascular diseases, to find out precisely which hereditary factors may distinguish people who are so-called aspirin-resistant or not, and why the medication works for most but not all.

"Our combined study results really do set the path for personalizing a lot of treatments for cardiovascular disease to people based on their genetic make up and who is likely to benefit most or not at all from these treatments," says Lewis Becker.


'/>"/>

Contact: David March
dmarch1@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
Source:Eurekalert

Related biology news :

1. Genetically modified cell procedure may prove useful in treating kidney failure
2. Freely available data supporting next generation of human genetic research
3. Should the results of individual genetic studies be disclosed to participants?
4. Small genetic variant can predict response to hepatitis C treatment
5. Genetics Society of America to host 2010 Yeast Genetics & Molecular Biology Meeting
6. New microbial genetic system dissects biomass to biofuel conversion
7. Autism genome project identifies genetic variants that may make people susceptible to disorder
8. Study finds epigenetic similarities between Wilms tumor cells and normal kidney stem cells
9. UT Southwestern researchers use novel sperm stem-cell technique to produce genetically modified rats
10. Genetics Society of America to host Model Organisms to Human Biology Meeting, June 12-15, 2010
11. AMP cautions consumers about direct access genetic testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ARMONK, N.Y. and ITHACA, N.Y. ... IBM ) and Cornell University, a leader in dairy ... combined with bioinformatics designed to help reduce the chances ... breaches. With the onset of this dairy project, Cornell ... the Consortium for Sequencing the Food Supply Chain, a ...
(Date:5/23/2017)... GENOA, Italy , May 23, 2017  Hunova, the first robotic ... and trunk, has been officially launched in Genoa, Italy ... Europe and the USA . The ... launched on the market by the IIT spin-off Movendo Technology thanks to ... view the Multimedia News Release, please click: ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik ... Winners and six Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. ... Foundation and administered by the New York Academy of Sciences to honor the ...
(Date:10/12/2017)... ... 12, 2017 , ... BioMedGPS announces expanded coverage of SmartTRAK ... module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and Sealants ... sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market will ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its national ... Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based ... selected for membership in ARCS Alumni Hall of Fame . ASTER Labs ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
Breaking Biology Technology: